Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as hormonal imbalance, congestive heart failure, nephrotic disorders, and obstructive sleep apnea are common causes of nocturnal polyuria. The primary objective of disease treatment is to curb urine production at night. Physicians manage the disease with lifestyle modifications initially before moving to pharmacotherapy. Desmopressin, branded as Noctiva (nasal spray) and Nocdurna (sublingual), are the only FDA-approved drugs currently available for nocturnal polyuria, though physicians also use midafternoon diuretics and tricyclic antidepressants to treat the condition. Importantly, desmopressin has a black box warning for hyponatremia, which further limits physicians’ options for disease management, providing market opportunity for agents to enter this space.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.